Smith & Nephew (LSE: SN; NYSE: SNN), the global medical technology business, today announces the launch of its DURAFIBER Ag antimicrobial dressing in the EU.
DURAFIBER is a highly absorbent, non-woven gelling fibre dressing that provides a versatile solution for the management of medium to heavily exuding chronic and acute wounds.
DURAFIBER Ag expands the range by adding the antimicrobial action of silver to this proven technology. DURAFIBER Ag is strong when wet, a key attribute in deeper wounds. Its composition facilitates clean, one-piece dressing removal, effective exudate management and uncompromised patient comfort, and its anti-shrinkage properties allows wounds to be treated efficiently.
DURAFIBER Ag was launched in the US in September 2013 and will now be available in the EU and other markets worldwide in the near future.
Frans Cromme, Senior Vice President, Advanced Wound Care, commented: “We believe it is important that clinicians have a choice when treating these type of wounds. Smith & Nephew is committed to delivering innovative products that improve patient wellbeing and help reduce the economic cost of wounds. I’m delighted that patients will now be able to benefit from the effectiveness of this new dressing with its high absorbency and proven clinical outcomes.”
Enquiries
Media
Sara Fisher +44 (0) 1482 673414
Smith & Nephew
Investors
Phil Cowdy +44 (0) 20 7401 7646
Smith & Nephew
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has around 11,000 employees and a presence in more than 90 countries. Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit: www.smith-nephew.com
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊ Trademark of Smith & Nephew. Registered US Patent and Trademark Office.